Replies to post #2726 on GTC Biotherapeutics (fka GTCB)

[go seek]

because the equivalent recombinant can be produced at a lower cost...

correct? ...

[DewDiligence]

ZGEN, Bayer Ink Deal for Recombinant Thrombin:
#msg-20562195.

Note: this is thrombin, not antithrombin. The relevance of this deal for GTC is indirect: the deal shows that Bayer thinks recombinant thrombin will be a commercial success due to its inherent safety advantage despite the fact that plasma-derived thrombin is widely available.